Literature DB >> 8062324

Selective serotonin reuptake inhibitor dose titration in the naturalistic setting.

K J Gregor1, J M Overhage, S J Coons, R C McDonald.   

Abstract

Little information exists regarding the use of selective serotonin reuptake inhibitors (SSRIs) in the naturalistic setting. The Regenstrief Medical Record System was used to analyze the dosing of SSRIs in the outpatient population of an urban teaching hospital. A cohort of 3350 patients was extracted, of whom 2859 had received fluoxetine and 460 sertraline. This cohort received 21,079 prescriptions. (The 31 patients who were prescribed paroxetine were eliminated from further analysis.) The mean daily dose for all patients receiving fluoxetine was 21 +/- 6 mg for the first prescription dispensed and 25 +/- 11 mg for the ninth. For fluoxetine-treated patients with depression included on their computerized medical problem list, the mean daily dose was 21 +/- 6 mg for the first prescription and 26 +/- 12 mg for the ninth. A mean of 5.0% of all patients continuing fluoxetine therapy had their daily dose increased with each prescription refill during the first nine prescriptions. The mean daily dose for all patients receiving sertraline was 59 +/- 28 mg for the first prescription and 117 +/- 66 mg for the ninth. For sertraline-treated patients with depression included on their computerized medical problem list, the mean daily dose was 57 +/- 25 mg for the first prescription and 110 +/- 65 mg for the ninth. A mean of 14.9% of all patients continuing sertraline therapy had their daily dose increased with each prescription refill during the first nine prescriptions. The frequency of sertraline dose increases was 2 to 3 times the rate for fluoxetine. Because increases in daily doses typically result from inadequate control of symptoms of depression, these findings may reflect fluoxetine's greater effectiveness in controlling symptoms during the initial stages of therapy in the naturalistic setting.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8062324

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  10 in total

1.  Dr. Marken Replies.

Authors:  Patricia A. Marken
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-10

Review 2.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 3.  Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls.

Authors:  P L Hensley; H G Nurnberg
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 5.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

6.  Systematic review and guide to selection of selective serotonin reuptake inhibitors.

Authors:  J G Edwards; I Anderson
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

7.  Expenditures associated with dose titration at initiation of therapy in patients with major depressive disorder: a retrospective analysis of a large managed care claims database.

Authors:  Fabian Camacho; Meg C Kong; David V Sheehan; Rajesh Balkrishnan
Journal:  P T       Date:  2010-08

8.  Antidepressant selection and use and healthcare expenditures. An empirical approach.

Authors:  W H Crown; T R Hylan; L Meneades
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

9.  Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial.

Authors:  Stephanie S O'Malley; Robert W Robin; Aryeh L Levenson; Iva GreyWolf; Lawrence E Chance; Colin A Hodgkinson; Denise Romano; Jane Robinson; Boris Meandzija; Verner Stillner; Ran Wu; David Goldman
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

10.  Selective serotonin reuptake inhibitor use in primary care: a 5-year naturalistic study.

Authors:  J Donoghue
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.